S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
Log in
NASDAQ:STRO

Sutro Biopharma Competitors

$20.29
-0.96 (-4.52 %)
(As of 03/4/2021 12:00 AM ET)
Add
Compare
Today's Range
$19.69
Now: $20.29
$21.78
50-Day Range
$21.25
MA: $24.52
$27.54
52-Week Range
$6.00
Now: $20.29
$28.30
Volume696,042 shs
Average Volume506,354 shs
Market Capitalization$783.28 million
P/E RatioN/A
Dividend YieldN/A
Beta0.8

Competitors

Sutro Biopharma (NASDAQ:STRO) Vs. RVMD, NK, EDIT, NSTG, SRNE, and ALVR

Should you be buying STRO stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Sutro Biopharma, including Revolution Medicines (RVMD), NantKwest (NK), Editas Medicine (EDIT), NanoString Technologies (NSTG), Sorrento Therapeutics (SRNE), and AlloVir (ALVR).

Sutro Biopharma (NASDAQ:STRO) and Revolution Medicines (NASDAQ:RVMD) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, dividends, valuation, analyst recommendations, earnings and institutional ownership.

Analyst Ratings

This is a summary of recent ratings and price targets for Sutro Biopharma and Revolution Medicines, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sutro Biopharma01602.86
Revolution Medicines01402.80

Sutro Biopharma currently has a consensus target price of $23.3333, indicating a potential upside of 15.00%. Revolution Medicines has a consensus target price of $50.75, indicating a potential upside of 19.55%. Given Revolution Medicines' higher probable upside, analysts plainly believe Revolution Medicines is more favorable than Sutro Biopharma.

Earnings and Valuation

This table compares Sutro Biopharma and Revolution Medicines' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sutro Biopharma$42.74 million18.33$-55,740,000.00($2.43)-8.35
Revolution Medicines$50.04 million56.31$-47,660,000.00N/AN/A

Revolution Medicines has higher revenue and earnings than Sutro Biopharma.

Profitability

This table compares Sutro Biopharma and Revolution Medicines' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sutro Biopharma27.60%-41.86%-29.50%
Revolution Medicines-191.17%-32.25%-20.55%

Insider & Institutional Ownership

78.8% of Sutro Biopharma shares are held by institutional investors. Comparatively, 85.8% of Revolution Medicines shares are held by institutional investors. 28.9% of Sutro Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Revolution Medicines beats Sutro Biopharma on 7 of the 11 factors compared between the two stocks.

Sutro Biopharma (NASDAQ:STRO) and NantKwest (NASDAQ:NK) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, dividends, valuation, analyst recommendations, earnings and institutional ownership.

Analyst Ratings

This is a summary of recent ratings and price targets for Sutro Biopharma and NantKwest, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sutro Biopharma01602.86
NantKwest00103.00

Sutro Biopharma currently has a consensus target price of $23.3333, indicating a potential upside of 15.00%. NantKwest has a consensus target price of $18.00, indicating a potential downside of 30.10%. Given Sutro Biopharma's higher probable upside, equities research analysts plainly believe Sutro Biopharma is more favorable than NantKwest.

Earnings and Valuation

This table compares Sutro Biopharma and NantKwest's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sutro Biopharma$42.74 million18.33$-55,740,000.00($2.43)-8.35
NantKwest$40,000.0070,166.82$-65,790,000.00($0.70)-36.79

Sutro Biopharma has higher revenue and earnings than NantKwest. NantKwest is trading at a lower price-to-earnings ratio than Sutro Biopharma, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Sutro Biopharma and NantKwest's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sutro Biopharma27.60%-41.86%-29.50%
NantKwest-76,658.58%-56.06%-46.93%

Volatility and Risk

Sutro Biopharma has a beta of 0.8, indicating that its stock price is 20% less volatile than the S&P 500. Comparatively, NantKwest has a beta of 2.61, indicating that its stock price is 161% more volatile than the S&P 500.

Insider & Institutional Ownership

78.8% of Sutro Biopharma shares are held by institutional investors. Comparatively, 9.4% of NantKwest shares are held by institutional investors. 28.9% of Sutro Biopharma shares are held by insiders. Comparatively, 71.7% of NantKwest shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Sutro Biopharma beats NantKwest on 8 of the 14 factors compared between the two stocks.

Sutro Biopharma (NASDAQ:STRO) and Editas Medicine (NASDAQ:EDIT) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, dividends, valuation, analyst recommendations, earnings and institutional ownership.

Insider & Institutional Ownership

78.8% of Sutro Biopharma shares are held by institutional investors. Comparatively, 87.5% of Editas Medicine shares are held by institutional investors. 28.9% of Sutro Biopharma shares are held by insiders. Comparatively, 0.9% of Editas Medicine shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Sutro Biopharma and Editas Medicine's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sutro Biopharma$42.74 million18.33$-55,740,000.00($2.43)-8.35
Editas Medicine$20.53 million132.43$-133,750,000.00($2.68)-15.06

Sutro Biopharma has higher revenue and earnings than Editas Medicine. Editas Medicine is trading at a lower price-to-earnings ratio than Sutro Biopharma, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and price targets for Sutro Biopharma and Editas Medicine, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sutro Biopharma01602.86
Editas Medicine34302.00

Sutro Biopharma currently has a consensus target price of $23.3333, indicating a potential upside of 15.00%. Editas Medicine has a consensus target price of $49.2222, indicating a potential upside of 21.96%. Given Editas Medicine's higher probable upside, analysts plainly believe Editas Medicine is more favorable than Sutro Biopharma.

Volatility and Risk

Sutro Biopharma has a beta of 0.8, indicating that its stock price is 20% less volatile than the S&P 500. Comparatively, Editas Medicine has a beta of 2.1, indicating that its stock price is 110% more volatile than the S&P 500.

Profitability

This table compares Sutro Biopharma and Editas Medicine's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sutro Biopharma27.60%-41.86%-29.50%
Editas Medicine-99.62%-26.74%-16.38%

Sutro Biopharma (NASDAQ:STRO) and NanoString Technologies (NASDAQ:NSTG) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, profitability, risk, analyst recommendations, dividends, earnings and institutional ownership.

Insider and Institutional Ownership

78.8% of Sutro Biopharma shares are owned by institutional investors. Comparatively, 98.3% of NanoString Technologies shares are owned by institutional investors. 28.9% of Sutro Biopharma shares are owned by insiders. Comparatively, 4.2% of NanoString Technologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Sutro Biopharma and NanoString Technologies' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sutro Biopharma$42.74 million18.33$-55,740,000.00($2.43)-8.35
NanoString Technologies$125.57 million21.41$-40,700,000.00($1.93)-31.61

NanoString Technologies has higher revenue and earnings than Sutro Biopharma. NanoString Technologies is trading at a lower price-to-earnings ratio than Sutro Biopharma, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Sutro Biopharma and NanoString Technologies, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sutro Biopharma01602.86
NanoString Technologies01502.83

Sutro Biopharma presently has a consensus target price of $23.3333, indicating a potential upside of 15.00%. NanoString Technologies has a consensus target price of $63.00, indicating a potential upside of 3.26%. Given Sutro Biopharma's stronger consensus rating and higher possible upside, research analysts clearly believe Sutro Biopharma is more favorable than NanoString Technologies.

Volatility and Risk

Sutro Biopharma has a beta of 0.8, indicating that its stock price is 20% less volatile than the S&P 500. Comparatively, NanoString Technologies has a beta of 1.77, indicating that its stock price is 77% more volatile than the S&P 500.

Profitability

This table compares Sutro Biopharma and NanoString Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sutro Biopharma27.60%-41.86%-29.50%
NanoString Technologies-53.47%-68.96%-24.15%

Summary

NanoString Technologies beats Sutro Biopharma on 8 of the 14 factors compared between the two stocks.

Sutro Biopharma (NASDAQ:STRO) and Sorrento Therapeutics (NASDAQ:SRNE) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, profitability, risk, analyst recommendations, dividends, earnings and institutional ownership.

Insider and Institutional Ownership

78.8% of Sutro Biopharma shares are owned by institutional investors. Comparatively, 27.4% of Sorrento Therapeutics shares are owned by institutional investors. 28.9% of Sutro Biopharma shares are owned by insiders. Comparatively, 3.4% of Sorrento Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Sutro Biopharma and Sorrento Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sutro Biopharma$42.74 million18.33$-55,740,000.00($2.43)-8.35
Sorrento Therapeutics$31.43 million78.73$-292,070,000.00($2.12)-4.16

Sutro Biopharma has higher revenue and earnings than Sorrento Therapeutics. Sutro Biopharma is trading at a lower price-to-earnings ratio than Sorrento Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Sutro Biopharma and Sorrento Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sutro Biopharma01602.86
Sorrento Therapeutics00403.00

Sutro Biopharma presently has a consensus target price of $23.3333, indicating a potential upside of 15.00%. Sorrento Therapeutics has a consensus target price of $28.75, indicating a potential upside of 226.33%. Given Sorrento Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Sorrento Therapeutics is more favorable than Sutro Biopharma.

Volatility and Risk

Sutro Biopharma has a beta of 0.8, indicating that its stock price is 20% less volatile than the S&P 500. Comparatively, Sorrento Therapeutics has a beta of 2.7, indicating that its stock price is 170% more volatile than the S&P 500.

Profitability

This table compares Sutro Biopharma and Sorrento Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sutro Biopharma27.60%-41.86%-29.50%
Sorrento Therapeutics-698.01%-314.06%-43.60%

Summary

Sutro Biopharma beats Sorrento Therapeutics on 8 of the 14 factors compared between the two stocks.

Sutro Biopharma (NASDAQ:STRO) and AlloVir (NASDAQ:ALVR) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, profitability, risk, analyst recommendations, dividends, earnings and institutional ownership.

Insider and Institutional Ownership

78.8% of Sutro Biopharma shares are owned by institutional investors. Comparatively, 32.1% of AlloVir shares are owned by institutional investors. 28.9% of Sutro Biopharma shares are owned by insiders. Comparatively, 1.0% of AlloVir shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Sutro Biopharma and AlloVir's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sutro Biopharma$42.74 million18.33$-55,740,000.00($2.43)-8.35
AlloVirN/AN/AN/AN/AN/A

AlloVir has lower revenue, but higher earnings than Sutro Biopharma.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Sutro Biopharma and AlloVir, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sutro Biopharma01602.86
AlloVir00403.00

Sutro Biopharma presently has a consensus target price of $23.3333, indicating a potential upside of 15.00%. AlloVir has a consensus target price of $48.75, indicating a potential upside of 41.18%. Given AlloVir's stronger consensus rating and higher possible upside, analysts clearly believe AlloVir is more favorable than Sutro Biopharma.

Profitability

This table compares Sutro Biopharma and AlloVir's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sutro Biopharma27.60%-41.86%-29.50%
AlloVirN/AN/AN/A

Summary

Sutro Biopharma beats AlloVir on 5 of the 9 factors compared between the two stocks.


Sutro Biopharma Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Revolution Medicines logo
RVMD
Revolution Medicines
1.6$42.45-1.7%$2.82 billion$50.04 million0.00Earnings Announcement
Analyst Report
NantKwest logo
NK
NantKwest
1.1$25.75-3.2%$2.81 billion$40,000.00-36.27Decrease in Short Interest
Gap Up
Editas Medicine logo
EDIT
Editas Medicine
1.4$40.36-6.9%$2.72 billion$20.53 million-23.20Analyst Report
NanoString Technologies logo
NSTG
NanoString Technologies
1.3$61.01-12.9%$2.69 billion$125.57 million-35.68Earnings Announcement
Analyst Report
Gap Up
Sorrento Therapeutics logo
SRNE
Sorrento Therapeutics
1.3$8.81-3.0%$2.47 billion$31.43 million-6.03Gap Up
AlloVir logo
ALVR
AlloVir
1.4$34.53-7.5%$2.25 billionN/A0.00Insider Selling
Kymera Therapeutics logo
KYMR
Kymera Therapeutics
0.8$45.86-1.9%$2.04 billionN/A0.00
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.1$10.92-8.7%$1.94 billion$48.83 million-14.37
bluebird bio logo
BLUE
bluebird bio
1.8$27.94-5.0%$1.88 billion$44.67 million-2.54Analyst Report
Vericel logo
VCEL
Vericel
1.5$40.41-4.2%$1.86 billion$117.85 million-4,041,000.00Analyst Report
Analyst Revision
Scholar Rock logo
SRRK
Scholar Rock
1.3$50.60-1.7%$1.70 billion$20.49 million-21.00Upcoming Earnings
News Coverage
Gap Up
Ocugen logo
OCGN
Ocugen
1.1$8.97-16.6%$1.69 billionN/A-6.06Analyst Report
Unusual Options Activity
Gap Up
C4 Therapeutics logo
CCCC
C4 Therapeutics
1.1$39.07-2.5%$1.68 billionN/A0.00
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$11.23-0.3%$1.61 billion$102.43 million-18.72Analyst Downgrade
Analyst Revision
Krystal Biotech logo
KRYS
Krystal Biotech
1.5$71.65-16.2%$1.59 billionN/A-48.41Earnings Announcement
Analyst Upgrade
Analyst Revision
Translate Bio logo
TBIO
Translate Bio
1.4$21.29-0.8%$1.58 billion$7.80 million-19.90Upcoming Earnings
Analyst Revision
News Coverage
Replimune Group logo
REPL
Replimune Group
1.5$32.30-1.3%$1.50 billionN/A-18.25News Coverage
REGENXBIO logo
RGNX
REGENXBIO
1.8$39.21-2.4%$1.47 billion$35.23 million-15.81Earnings Announcement
Analyst Downgrade
Analyst Revision
FMTX
Forma Therapeutics
1.8$33.42-8.4%$1.38 billion$100.56 million0.00Decrease in Short Interest
Atara Biotherapeutics logo
ATRA
Atara Biotherapeutics
1.6$15.89-0.4%$1.33 billionN/A-3.44Earnings Announcement
Analyst Upgrade
Analyst Revision
Alector logo
ALEC
Alector
1.3$16.25-1.0%$1.29 billion$21.22 million-7.29Analyst Upgrade
Immunovant logo
IMVT
Immunovant
1.8$13.08-7.0%$1.28 billionN/A-10.14Increase in Short Interest
PCVX
Vaxcyte
1.8$23.62-9.4%$1.20 billionN/A0.00Insider Selling
Coherus BioSciences logo
CHRS
Coherus BioSciences
1.4$15.25-1.2%$1.11 billion$356.07 million7.47Analyst Report
Mesoblast logo
MESO
Mesoblast
1.4$9.18-0.3%$1.08 billion$32.16 million-10.43Earnings Announcement
Analyst Upgrade
Analyst Revision
Cortexyme logo
CRTX
Cortexyme
1.3$36.37-3.2%$1.07 billionN/A-15.15Earnings Announcement
Adverum Biotechnologies logo
ADVM
Adverum Biotechnologies
1.7$10.96-3.1%$1.07 billion$250,000.00-8.63Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Inhibrx logo
INBX
Inhibrx
1.7$26.56-9.9%$1.00 billionN/A0.00
Aerie Pharmaceuticals logo
AERI
Aerie Pharmaceuticals
1.7$19.25-1.6%$903.15 million$69.89 million-4.59
Passage Bio logo
PASG
Passage Bio
1.9$19.43-2.7%$892.17 millionN/A0.00Earnings Announcement
Analyst Upgrade
News Coverage
Gap Down
Taysha Gene Therapies logo
TSHA
Taysha Gene Therapies
1.8$23.40-7.7%$883.61 millionN/A0.00Earnings Announcement
Analyst Report
News Coverage
Gap Down
Black Diamond Therapeutics logo
BDTX
Black Diamond Therapeutics
1.6$23.73-8.0%$857.03 millionN/A-3.92News Coverage
Rubius Therapeutics logo
RUBY
Rubius Therapeutics
1.7$10.40-10.4%$844.29 millionN/A-4.86
Aligos Therapeutics logo
ALGS
Aligos Therapeutics
1.5$21.54-12.1%$821.06 millionN/A0.00
Cellectis logo
CLLS
Cellectis
1.2$19.31-4.3%$820.41 million$22.99 million-10.27
TCR2 Therapeutics logo
TCRR
TCR2 Therapeutics
1.5$24.06-6.9%$804.13 millionN/A-9.94
Adaptimmune Therapeutics logo
ADAP
Adaptimmune Therapeutics
1.6$5.01-4.8%$775.44 million$1.12 million-5.06Analyst Upgrade
Vaxart logo
VXRT
Vaxart
1.3$5.92-7.4%$697.18 million$9.86 million-10.03Analyst Report
Gap Up
Orchard Therapeutics logo
ORTX
Orchard Therapeutics
1.6$6.86-7.3%$667.23 million$2.51 million-4.16Earnings Announcement
Analyst Report
Increase in Short Interest
Athira Pharma logo
ATHA
Athira Pharma
2.2$19.29-6.8%$626.64 millionN/A0.00Decrease in Short Interest
News Coverage
Tarsus Pharmaceuticals logo
TARS
Tarsus Pharmaceuticals
1.4$30.61-8.2%$622.00 millionN/A0.00Increase in Short Interest
Gap Down
Agenus logo
AGEN
Agenus
1.6$3.16-7.3%$600.87 million$150.05 million-2.90
Precision BioSciences logo
DTIL
Precision BioSciences
1.5$11.02-3.1%$578.33 million$22.24 million-5.48Upcoming Earnings
Analyst Report
Poseida Therapeutics logo
PSTX
Poseida Therapeutics
1.9$9.28-17.0%$573.69 millionN/A-1.35
Compugen logo
CGEN
Compugen
1.4$8.16-9.2%$558.31 million$17.80 million-22.05Analyst Downgrade
DBV Technologies logo
DBVT
DBV Technologies
1.2$5.02-7.6%$551.49 million$14.75 million-2.15Gap Up
Curis logo
CRIS
Curis
1.3$9.13-6.4%$537.00 million$10 million-11.13Increase in Short Interest
MeiraGTx logo
MGTX
MeiraGTx
1.4$13.90-2.5%$533.93 million$13.29 million-9.86Upcoming Earnings
News Coverage
Solid Biosciences logo
SLDB
Solid Biosciences
1.1$8.83-12.0%$533.77 millionN/A-4.29Upcoming Earnings
Oyster Point Pharma logo
OYST
Oyster Point Pharma
1.7$20.44-2.7%$529.60 millionN/A-5.89
This page was last updated on 3/5/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.